Skip to main content

Articles

Page 12 of 67

  1. The presence of headache during the acute phase of COVID-19 could be associated with the innate response and the cytokine release. We aim to compare the cytokine and interleukin profile in hospitalized COVID-1...

    Authors: Javier Trigo, David García-Azorín, Álvaro Sierra-Mencía, Álvaro Tamayo-Velasco, Pedro Martínez-Paz, Eduardo Tamayo, Angel Luis Guerrero and Hugo Gonzalo-Benito
    Citation: The Journal of Headache and Pain 2021 22:51
    Content type: Research article Published on:

  2. Chronic migraine (CM) is associated with substantial economic burden. Real-world data suggests that onabotulinumtoxinA treatment for CM reduces healthcare resource utilisation (HRU) and related costs.

    Authors: Katja Kollewe, Charly Gaul, Astrid Gendolla and Katherine Sommer
    Citation: The Journal of Headache and Pain 2021 22:50
    Content type: Research article Published on:

  3. Headache disorders are highly prevalent worldwide, but not well investigated in adolescents. Few studies have included representative nationwide samples. This study aimed to present the prevalence and burden o...

    Authors: Margot J. Wilkes, M. Dilani Mendis, Leanne Bisset, Felix T. Leung, Christopher T. Sexton and Julie A. Hides
    Citation: The Journal of Headache and Pain 2021 22:49
    Content type: Research article Published on:

  4. Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migrai...

    Authors: Jakub Jedynak, Eric Eross, Astrid Gendolla, Mallikarjuna Rettiganti and Virginia L. Stauffer
    Citation: The Journal of Headache and Pain 2021 22:48
    Content type: Research article Published on:

  5. Preceding studies have reported the association of chronic neuropathic orofacial pain with altered ongoing function in the ventrolateral periaqueductal gray (vlPAG). However, its role in trigeminal neuralgia (...

    Authors: K. C. Elina, Byeong Ho Oh, Jaisan Islam, Soochong Kim and Young Seok Park
    Citation: The Journal of Headache and Pain 2021 22:47
    Content type: Research article Published on:

  6. Authors: Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjørn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell and Lahar Mehta
    Citation: The Journal of Headache and Pain 2021 22:46
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2021 22:16

  7. Migraine is a neurological, primary headache disorder affecting more than 1 billion people worldwide, with a multi-faceted burden that can significantly impact the everyday life of a patient, both during and b...

    Authors: Byung-Kun Kim, Min Kyung Chu, Soo Jin Yu, Grazia Dell’Agnello, Jeong Hee Han and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2021 22:45
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:56

  8. Post-traumatic trigeminal neuropathy (PTN) can have a substantial effect on patient well-being. However, the relation between the neuropathic symptoms and their effect on psychosocial functioning remains a mat...

    Authors: Jeroen Meewis, Tara Renton, Reinhilde Jacobs, Constantinus Politis and Fréderic Van der Cruyssen
    Citation: The Journal of Headache and Pain 2021 22:44
    Content type: Research article Published on:

  9. There is currently a wide therapeutic arsenal for migraine patients, without a single first-line preventive drug and we choose the different available alternatives taking into account comorbidities, national g...

    Authors: AB Gago-Veiga, J-I Huhn, N Latysheva, A Vieira Campos, M Torres-Ferrus, A Alpuente Ruiz, S Sacco, I Frattale, R Ornello, R Ruscheweyh, IB Marques, A Gryglas-Dworak, C Stark, VJ Gallardo and P Pozo-Rosich
    Citation: The Journal of Headache and Pain 2021 22:43
    Content type: Research article Published on:

  10. Headache attributed to Temporomandibular Disorder (HATMD) is a secondary headache that may have features resulting in diagnostic overlap with primary headaches, namely, tension-type (TTH) or migraine. This cro...

    Authors: Inna E. Tchivileva, Richard Ohrbach, Roger B. Fillingim, Feng-Chang Lin, Pei Feng Lim, Samuel J. Arbes Jr and Gary D. Slade
    Citation: The Journal of Headache and Pain 2021 22:42
    Content type: Research article Published on:

  11. Coronavirus disease 2019 (COVID-19) bring about a range of psychological distress and symptom deterioration to headache patients especially to some migraineurs. Compared to migraineurs or normal control, medic...

    Authors: Changling Li, Yanbo Li, Mengmeng Ma, Yang Zhang, Jiajia Bao, Wenjing Ge, Yanqin Liu, Cheng Peng and Li He
    Citation: The Journal of Headache and Pain 2021 22:41
    Content type: Research article Published on:

  12. Migraine is a common neurological disease that is often accompanied by psychiatric comorbidities. However, the relationship between abnormal brain function and psychiatric comorbidities in migraine patients re...

    Authors: Heng-Le Wei, Jian Li, Xi Guo, Gang-Ping Zhou, Jin-Jin Wang, Yu-Chen Chen, Yu-Sheng Yu, Xindao Yin, Junrong Li and Hong Zhang
    Citation: The Journal of Headache and Pain 2021 22:40
    Content type: Research article Published on:

  13. New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for treatment e...

    Authors: Simona Sacco, Christian Lampl, Antoinette Maassen van den Brink, Valeria Caponnetto, Mark Braschinsky, Anne Ducros, Patrick Little, Patricia Pozo-Rosich, Uwe Reuter, Elena Ruiz de la Torre, Margarita Sanchez Del Rio, Alexandra J. Sinclair, Paolo Martelletti and Zaza Katsarava
    Citation: The Journal of Headache and Pain 2021 22:39
    Content type: Research article Published on:

  14. In this study, we investigated the possible analgesic effects of Botulinum toxin type A (BoNT/A) on trigeminal neuralgia (TN). A modified TN mouse model was established by chronic constriction injury of the di...

    Authors: Wei-Jia Chen, Jing-Qi Niu, Yi-Ting Chen, Wen-Jing Deng, Ying-Ying Xu, Jing Liu, Wei-Feng Luo and Tong Liu
    Citation: The Journal of Headache and Pain 2021 22:38
    Content type: Research article Published on:

  16. Behaviors of substance dependence are common among patients with medication-overuse headache (MOH). Whether MOH, like other substance use disorders, is associated with an increased risk for suicide is unknown.

    Authors: Yen-Feng Wang, Chia-Chun Yu, Ai Seon Kuan, Shih-Pin Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2021 22:36
    Content type: Research article Published on:

  17. The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galc...

    Authors: Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati, Marco Aguggia, Florindo d’Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Renata Rao…
    Citation: The Journal of Headache and Pain 2021 22:35
    Content type: Research article Published on:

  18. As a disorder of brain dysfunction, migraine has been associated with cognitive decline. However, no consistent results with respect to the attention function in migraineurs have been found, and the relationsh...

    Authors: Min Su, Rongfei Wang, Zhao Dong, Dengfa Zhao and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2021 22:34
    Content type: Research article Published on:

  19. Lifting The Burden (LTB) and European Headache Federation (EHF) have developed a set of headache service quality indicators, successfully tested in specialist headache centres. Their intended application includes...

    Authors: B. Lenz, Z. Katsarava, R. Gil-Gouveia, G. Karelis, B. Kaynarkaya, L. Meksa, E. Oliveira, F. Palavra, I. Rosendo, M. Sahin, B. Silva, D. Uludüz, Y. Z. Ural, I. Varsberga-Apsite, S. T. Zengin, L. Zvaune…
    Citation: The Journal of Headache and Pain 2021 22:33
    Content type: Research article Published on:

  20. Chronic headache is particularly prevalent in migraineurs and it can progress to a condition known as medication overuse headache (MOH). MOH is a secondary headache caused by overuse of analgesics or other med...

    Authors: Tatiane Teru Takahashi, Raffaele Ornello, Giuseppe Quatrosi, Angelo Torrente, Maria Albanese, Simone Vigneri, Martina Guglielmetti, Cristiano Maria De Marco, Camille Dutordoir, Enrico Colangeli, Matteo Fuccaro, Davide Di Lenola, Valerio Spuntarelli, Laura Pilati, Salvatore Di Marco, Annelies Van Dycke…
    Citation: The Journal of Headache and Pain 2021 22:32
    Content type: Review article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:64

  21. Trigeminal neuralgia is a characteristic disease that manifests as orofacial phasic or continuous severe pain triggered by innocuous orofacial stimulation; its mechanisms are not fully understood. In this stud...

    Authors: Momoko Koizumi, Sayaka Asano, Akihiko Furukawa, Yoshinori Hayashi, Suzuro Hitomi, Ikuko Shibuta, Katsuhiko Hayashi, Fusao Kato, Koichi Iwata and Masamichi Shinoda
    Citation: The Journal of Headache and Pain 2021 22:31
    Content type: Research article Published on:

  22. Episodic headache with spontaneous hypothermia constitute an uncommon association and is not well recognized in the International Classification of Headache Disorders (ICHD-3). Spontaneous periodic hypothermia...

    Authors: Mickael Aubignat, Melissa Tir, Pierre Krystkowiak and Daniela Andriuta
    Citation: The Journal of Headache and Pain 2021 22:30
    Content type: Case report Published on:

  23. Migraine is the leading cause of days lost due to disability in the world among people less than 50 years of age. There is a paucity of evidence on the impact of migraine and other headache disorders and the c...

    Authors: Toshihiko Shimizu, Fumihiko Sakai, Hitoshi Miyake, Tomofumi Sone, Mitsuhiro Sato, Satoshi Tanabe, Yasuhiro Azuma and David W. Dodick
    Citation: The Journal of Headache and Pain 2021 22:29
    Content type: Research article Published on:

  24. To determine the frequency of suicidal ideation and assess suicide risk in cluster headache (CH) patients compared to matched controls without CH in this observational case-control study.

    Authors: Brian B. Koo, Ahmed Bayoumi, Abdalla Albanna, Mohammed Abusuliman, Laura Burrone, Jason J. Sico and Emmanuelle A. D. Schindler
    Citation: The Journal of Headache and Pain 2021 22:28
    Content type: Research article Published on:

  25. Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. This study aimed to evaluate real-...

    Authors: Stewart J. Tepper, Juanzhi Fang, Pamela Vo, Ying Shen, Lujia Zhou, Ahmad Abdrabboh, Mrudula Glassberg and Matias Ferraris
    Citation: The Journal of Headache and Pain 2021 22:27
    Content type: Research article Published on:

  26. The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespe...

    Authors: Egilius L. H. Spierings, Mikko Kärppä, Xiaoping Ning, Joshua M. Cohen, Verena Ramirez Campos, Ronghua Yang and Uwe Reuter
    Citation: The Journal of Headache and Pain 2021 22:26
    Content type: Research article Published on:

  27. Granger causality analysis (GCA) has been used to investigate the pathophysiology of migraine. Amygdala plays a key role in pain modulation of migraine attack. However, the detailed neuromechanism remained to ...

    Authors: Xiaobin Huang, Di Zhang, Peng Wang, Cunnan Mao, Zhengfei Miao, Chunmei Liu, Chenjie Xu, Xindao Yin and Xinying Wu
    Citation: The Journal of Headache and Pain 2021 22:25
    Content type: Research article Published on:

  28. We recently showed headache to be common in children (aged 7–11 years) and adolescents (aged 12–17) in Lithuania. Here we provide evidence from the same study of the headache-attributable burden.

    Authors: Diana Genc, Nerija Vaičienė-Magistris, Apolinaras Zaborskis, Tayyar Şaşmaz, Aylin Yeniocak Tunç, Derya Uluduz, Christian Wöber, Çiçek Wöber-Bingöl and Timothy J. Steiner
    Citation: The Journal of Headache and Pain 2021 22:24
    Content type: Research article Published on:

  29. Butterbur root extract with its active ingredients petasin and isopetasin has been used in the prophylactic treatment of migraine for years, while its sites of action are not completely clear. Calcitonin gene-...

    Authors: Johanna Kleeberg-Hartmann, Birgit Vogler and Karl Messlinger
    Citation: The Journal of Headache and Pain 2021 22:23
    Content type: Research article Published on:

  30. Headache and facial pain are among the most common, disabling and costly diseases in Europe, which demands for high quality health care on all levels within the health system. The role of the Danish Headache S...

    Authors: Henrik W. Schytz, Faisal M. Amin, Rigmor H. Jensen, Louise Carlsen, Stine Maarbjerg, Nunu Lund, Karen Aegidius, Lise L. Thomsen, Flemming W. Bach, Dagmar Beier, Hanne Johansen, Jakob M. Hansen, Helge Kasch, Signe B. Munksgaard, Lars Poulsen, Per Schmidt Sørensen…
    Citation: The Journal of Headache and Pain 2021 22:22
    Content type: Consensus article Published on:

  31. This study aimed to assess the efficacy of concurrent magnesium-sodium valproate therapy and compare it with either magnesium or sodium valproate alone in migraine prophylaxis.

    Authors: Samira Khani, Seyed Amir Hejazi, Mehdi Yaghoubi and Ehsan Sharifipour
    Citation: The Journal of Headache and Pain 2021 22:21
    Content type: Research article Published on:

  33. With headache experienced by up to 75% of adults worldwide in the last year, primary headache disorders constitute a major public health problem, yet they remain under-diagnosed and under-treated.

    Authors: Peter J. Goadsby, Michel Lantéri-Minet, Martin C. Michel, Mario Peres, Mamoru Shibata, Andreas Straube, Tissa Wijeratne, Caty Ebel-Bitoun, Luminita Constantin and Simon Hitier
    Citation: The Journal of Headache and Pain 2021 22:19
    Content type: Commentary Published on:

  34. Existent animal models of migraine are not without drawbacks and limitations. The aim of our study was to evaluate imaging photoplethysmography (PPG) as a method of assessing intracranial blood flow in rats an...

    Authors: Alexey Y. Sokolov, Maxim A. Volynsky, Valery V. Zaytsev, Anastasiia V. Osipchuk and Alexei A. Kamshilin
    Citation: The Journal of Headache and Pain 2021 22:18
    Content type: Research article Published on:

  35. The topical inflammatory soup can model the inflammation of the dura mater causing hypersensitivity and activation of the trigeminal system, a phenomenon present in migraineurs. Calcitonin gene-related peptide...

    Authors: Eleonóra Spekker, Klaudia Flóra Laborc, Zsuzsanna Bohár, Gábor Nagy-Grócz, Annamária Fejes-Szabó, Mónika Szűcs, László Vécsei and Árpád Párdutz
    Citation: The Journal of Headache and Pain 2021 22:17
    Content type: Research article Published on:

  36. The humanized anti-CGRP monoclonal antibody eptinezumab has been evaluated in five large-scale clinical trials conducted in patients with migraine. This integrated analysis was conducted to evaluate the compre...

    Authors: Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjørn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell and Lahar Mehta
    Citation: The Journal of Headache and Pain 2021 22:16
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:46

  37. Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine. Galcanezumab demonstrated early onset of effect in patie...

    Authors: Todd J. Schwedt, Dulanji K. Kuruppu, Yan Dong, Katherine Standley, Laura Yunes-Medina and Eric Pearlman
    Citation: The Journal of Headache and Pain 2021 22:15
    Content type: Research article Published on:

  38. Chronic headache may persist after the remission of reversible cerebral vasoconstriction syndrome (RCVS) in some patients. We aimed to investigate the prevalence, characteristics, risk factors, and the impact ...

    Authors: Yu-Hsiang Ling, Yen-Feng Wang, Jiing-Feng Lirng, Jong-Ling Fuh, Shuu-Jiun Wang and Shih-Pin Chen
    Citation: The Journal of Headache and Pain 2021 22:14
    Content type: Research article Published on:

  39. Neurosteroids affect the balance between neuroexcitation and neuroinhibition but have been little studied in migraine. We compared the serum levels of pregnenolone sulfate, pregnanolone and estradiol in women ...

    Authors: Cecilia Rustichelli, Elisa Bellei, Stefania Bergamini, Emanuela Monari, Flavia Lo Castro, Carlo Baraldi, Aldo Tomasi and Anna Ferrari
    Citation: The Journal of Headache and Pain 2021 22:13
    Content type: Short report Published on:

  40. The mechanisms of genotype-phenotype interaction in Familiar Hemiplegic migraine type 2 (FHM2) are still far from clear. Different ATP1A2 mutations have been described, with a spectrum of phenotypes ranging from ...

    Authors: Fabio Antonaci, Sabrina Ravaglia, Gaetano S. Grieco, Stella Gagliardi, Cristina Cereda and Alfredo Costa
    Citation: The Journal of Headache and Pain 2021 22:12
    Content type: Case report Published on:

  42. Migraine is one of the most common neurological diseases around the world and calcitonin gene-related peptide (CGRP) plays an important role in its pathophysiology. Therefore, in the present study, we evaluate...

    Authors: Zeya Yan, Tao Xue, Shujun Chen, Xin Wu, Xingyu Yang, Guangjie Liu, Shan Gao, Zhouqing Chen and Zhong Wang
    Citation: The Journal of Headache and Pain 2021 22:10
    Content type: Research article Published on:

  43. Idiopatic trigeminal neuralgia purely paroxysmal (ITNp) distributed in the supraorbital and suprathrochlear dermatomes (SSd), refractory to conventional treatments have been linked to the hyperactivity of the ...

    Authors: Alessandro Gualdi, Janos Cambiaso-Daniel, Jonatann Gatti, Ziv M. Peled, Robert Hagan, Dario Bertossi, Paul Wurzer, Lars-Peter Kamolz, Saja Scherer and Giorgio Pietramaggiori
    Citation: The Journal of Headache and Pain 2021 22:9
    Content type: Research article Published on:

  44. Migraine is a primary headache disorder that can be classified into an episodic (EM) and a chronic form (CM). Network analysis within the graph-theoretical framework based on connectivity patterns provides an ...

    Authors: Lars Michels, Nabin Koirala, Sergiu Groppa, Roger Luechinger, Andreas R. Gantenbein, Peter S. Sandor, Spyros Kollias, Franz Riederer and Muthuraman Muthuraman
    Citation: The Journal of Headache and Pain 2021 22:8
    Content type: Research article Published on:

  45. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jasem Y. Al-Hashel, R. Alroughani, S. Shuaibi, A. AlAshqar, F. AlHamdan, H. AlThufairi, S. Owayed and Samar F. Ahmed
    Citation: The Journal of Headache and Pain 2021 22:7
    Content type: Correction Published on:

    The original article was published in The Journal of Headache and Pain 2020 21:80

  46. Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data...

    Authors: Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman and Sheena K. Aurora
    Citation: The Journal of Headache and Pain 2021 22:6
    Content type: Research article Published on:

    The Correction to this article has been published in The Journal of Headache and Pain 2021 22:100

  47. The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of eren...

    Authors: J. Talbot, R. Stuckey, L. Crawford, S. Weatherby and S. Mullin
    Citation: The Journal of Headache and Pain 2021 22:5
    Content type: Research article Published on:

  48. The moment-to-moment variability of resting-state brain activity has been suggested to play an active role in chronic pain. Here, we investigated the regional blood-oxygen-level-dependent signal variability (BOLD

    Authors: Manyoel Lim, Hassan Jassar, Dajung J. Kim, Thiago D. Nascimento and Alexandre F. DaSilva
    Citation: The Journal of Headache and Pain 2021 22:4
    Content type: Research article Published on:

  49. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown...

    Authors: Joshua M. Cohen, Xiaoping Ning, Yoel Kessler, Michele Rasamoelisolo, Verena Ramirez Campos, Michael J. Seminerio, Lynda J. Krasenbaum, Honglue Shen and Jennifer Stratton
    Citation: The Journal of Headache and Pain 2021 22:3
    Content type: Review article Published on:

  50. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine p...

    Authors: Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann and Michael J. Marmura
    Citation: The Journal of Headache and Pain 2021 22:2
    Content type: Research article Published on:
Submit manuscript

Official journal of

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.1 - 5-year Impact Factor
    2.002 - SNIP (Source Normalized Impact per Paper)
    1.593 - SJR (SCImago Journal Rank)

    2023 Speed
    3 days submission to first editorial decision for all manuscripts (Median)
    44 days submission to accept (Median)

    2023 Usage
    3,022,321 downloads
    3,296 Altmetric mentions 

  • ISSN: 1129-2377 (electronic)
  • ISSN: 1129-2369 (print)

Related reading

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us